Zifanocycline is under clinical development by KBP Biosciences and currently in Phase I for Community-Acquired Bacterial Pneumonia. According to GlobalData, Phase I drugs for Community-Acquired Bacterial Pneumonia have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Zifanocycline’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zifanocycline (KBP-7072) is under development for the treatment of acute bacterial skin and skin structure infections (ABSSI), community-acquired bacterial pneumonia (CABP), methicillin-resistant staphylococcus aureus (MRSA) infections, penicillin-resistant streptococcus pneumoniae (PRSP), vancomycin-resistant enterococcus (VRE) infections and Acinetobacter infections. It acts by targeting 30S ribosomal subunit (30S RNA). The drug candidate is an aminomethylcycline antibiotic, administered through oral and intravenous route.
KBP Biosciences overview
KBP Biosciences is a biopharmaceutical company that discovers, develops and commercializes small molecule drugs to treat cardiorenal and infectious diseases. The company’s lead product candidate KBP-5074, a non-steroidal mineralocorticoid receptor antagonist (MRA) is used for the treatment of uncontrolled hypertension in patients with chronic kidney diseases. KBP Biosciences is also investigating KBP-7072, a tetracycline formulation targeting multi drug resistant bacteria infections; KPB-7026 against eosinophilic asthma; KBP-8017, a multi kinase inhibitor to treat fibrosis caused due to radiotherapy; and KBP-7909 drug targeting gram negative bacterial infections. Its proprietary discovery platform helps in estimating pharmacokinetics/pharmacodynamics (PK/PD) and toxicology across various drug candidates. The company has operations in the US. KBP BioSciences is headquartered in Shanghai, China.
For a complete picture of Zifanocycline’s drug-specific PTSR and LoA scores, buy the report here.